Cantor Fitzgerald initiated coverage of AbCellera (ABCL) with an Overweight rating and $7 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABCL:
- AbCellera: Strategic Pivot to an Internal Pipeline and Key ABCL635 Readouts Position Shares for Multibillion-Dollar Upside
- AbCellera target is profile more attractive than Vistagen, says JonesResearch
- AbCellera: De-Risked Antibody Platform With High-Value Menopause Lead and Underappreciated Pipeline Optionality Supporting Buy Rating
- AbCellera initiated with a Buy at JonesResearch